10x Genomics (TXG) Current Deferred Revenue (2018 - 2026)

10x Genomics has reported Current Deferred Revenue for 9 years, with the latest figure at $24.3 million in Q1 2026.

• Quarterly Current Deferred Revenue fell 27.38% year-over-year to $24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.3 million (down 27.38% YoY) and the FY2025 annual result came in at $34.4 million, up 3.71% from the prior year.
• Current Deferred Revenue declined to $24.3 million in Q1 2026 per TXG's latest filing, from $34.4 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $34.4 million in Q4 2025 and troughed at $6.5 million in Q2 2022.
• A 5-year average of $19.6 million and a median of $21.4 million in 2025 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2026: Current Deferred Revenue surged 201.62% in 2024, then dropped 27.38% in 2026.
• Over 5 years, Current Deferred Revenue stood at $11.0 million in 2022, then soared by 99.09% to $22.0 million in 2023, then soared by 51.02% to $33.2 million in 2024, then advanced by 3.71% to $34.4 million in 2025, then decreased by 29.24% to $24.3 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $24.3 million, $34.4 million, and $22.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.